Because TERT is expressed in >90% cancers in humans, affects cancer cells at every stage of cancer differentiation, and TERT promoter mutations are very frequent in the cancer genome, we argue that TERT remains an ideal conserved self-tumor antigen for immunological interventions to curb cancer cell growth and prolong patient survival [62]. This evidence concerns the gene TERT and neoplasm.